China NMPA Inspection - Sichuan Provincial Drug Administration Office - December 02, 2021

The Sichuan Provincial Drug Administration, acting on a directive from the National Medical Products Administration (NMPA), issued a notice on December 2, 2021, detailing intensified requirements for the 2021 Cosmetics Supervision and Sampling Inspection Work. This initiative aims to enhance the verification and handling of unqualified cosmetic products identified during provincial and national sampling inspections throughout 2021, with a reporting deadline for actions set for December 10th.

The document outlines several critical issues, including the presence of unqualified products in the market, operators failing to maintain proper purchase inspection records, and entities providing false information or denying responsibility for substandard items. The regulatory framework governing these actions is primarily the *Cosmetics Supervision and Administration Regulations*, supplemented by NMPA's comprehensive cosmetics notice (No. 91 [2021]) and Sichuan's inspection guidelines (No. 34 [2021]).

Required actions include diligent verification and processing of all abnormal sampling situations, delivery of non-compliant product reports, and proper product confirmation. Market supervision bureaus and inspection branches must strengthen the tracing and source management of all unqualified products. Severe penalties will be levied against registrants, filers, entrusted manufacturers, and domestic responsible persons who provide false information or conceal facts regarding substandard products, without exceptions for operators failing to fulfill their obligations.